The regulation of the cell cycle is a fundamental process ensuring the accurate replication and division of cells. Central to this regulation are the Cdc25 phosphatases, which activate ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

The ability of mutations to cause cancer depends on how fast they force cells to divide, Sinai Health researchers have found. The study, led by Dr. Rod Bremner, a Senior Investigator at the ...

Scientists have discovered that a rare “mirror-image” version of the amino acid cysteine can dramatically slow the growth of ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells that dramatically prolongs their effectiveness after being infused into ...

Cancer begins when mutations in specific genes override the body’s built-in controls on cell division, allowing rogue cells ...

Scientists at École Polytechnique Fédérale Lausanne (EPFL), and at UNIL-CHUV, University Hospital Lausanne (CHUV) and University of Lausanne (UNIL) have developed a computational method to create ...

Researchers at the University of Chicago have developed a modular cancer immunotherapy that can be switched on, off or reprogramed to attack different cancers. Promising initial testing results, ...

A fasting-derived ketone metabolite reshapes CAR T cell metabolism and gene activity, boosting immune cell expansion, energy ...

In 2016, Colinda Scheele, a cancer biologist at Catholic University Leuven, was studying how chemotherapy affects breast cancer cells in mice. However, she observed an inconsistency: Some cell ...